Number of the records: 1
Synergy of short antimicrobial peptides with β-lactam antibiotics against MRSA resides in the degradation of peptidoglycan barrier
- 1.
SYSNO ASEP 0522930 Document Type C - Proceedings Paper (int. conf.) R&D Document Type The record was not marked in the RIV Title Synergy of short antimicrobial peptides with β-lactam antibiotics against MRSA resides in the degradation of peptidoglycan barrier Author(s) Nešuta, Ondřej (UOCHB-X) RID, ORCID
Kyznar, Jakub (UOCHB-X)
Volejníková, Andrea (UOCHB-X)
Čeřovský, Václav (UOCHB-X) RID, ORCIDSource Title Proceedings of the 35th European Peptide Symposium. - Dublin : European Peptide Society, 2018 / Timmons P. ; Hewage C. ; Lebl M. Pages s. 217-219 Number of pages 3 s. Publication form Print - P Action European Peptide Symposium /35./ Event date 26.08.2018 - 31.08.2018 VEvent location Dublin Country IE - Ireland Event type EUR Language eng - English Country IE - Ireland Keywords antimicrobial peptides ; MRSA ; peptidoglycan ; beta-lactams ; synergy Subject RIV EE - Microbiology, Virology OECD category Microbiology R&D Projects NV16-27726A GA MZd - Ministry of Health (MZ) Institutional support UOCHB-X - RVO:61388963 DOI 10.17952/35EPS.2018.217 Annotation The emerging resistance of bacteria to currently used antibiotics is becoming a significant global problem that requires searching for alternative antimicrobial agents. One of the most frequently reported pathogens, methicillin-resistant Staphylococcus aureus (MRSA), which causes infections of wounds, bones, implants, bloodstream, skin, pneumonia, etc., is a typical example of Gram-positive bacterium that possess resistance to several antibiotics, including β-lactams. Therapeutic options are becoming limited, and vancomycin remains as the last resort for treating MRSA, but not for long. Antimicrobial peptides (AMPs) have long been considered as a possible new class of anti-infective agents that could be used as a supplement to, or substitute for, conventional antibiotics in the fight against multi-drug resistant bacteria. Their potential advantage resides in a unique mechanism of action that involves interacting with the negatively charged phospholipid bilayer of bacterial cell membrane causing its disruption via pore formation or detergent-like disintegration, thereby leading to cell death. However, in Gram-positive bacteria, AMPs have to first pass through the cell wall that consists prevalently of a peptidoglycan layer, before reaching its target - the cytoplasmic membrane. Several reports have shown a significant synergistic antimicrobial effect when AMPs were applied in combination with common antibiotics. In this work, we examined a combination of short linear AMPs, previously invented in our laboratory, with β-lactam antibiotics against a reference strain of MRSA (ATCC 43300) in order to shed light on the mechanism of the synergy between AMPs and β-lactam antibiotics.
Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418 Year of Publishing 2020
Number of the records: 1